Left Ventricular Assist Devices

Joe L. Hsu and Rachel H. Dotson

BACKGROUND

Heart failure affects over 6 million people in the United States and accounts for 1 million hospital admissions annually.^1,2 Despite this prevalence, the number of hearts transplanted annually in the United States has remained fixed over the past decade at approximately 2,000 per year.³ In response to the disparity between need for transplantation and organ availability, in 1994, the U.S. Food and Drug Administration approved the use of left ventricular assist devices (LVADs) for patients awaiting heart transplantation and more recently for long-term support (i.e., destination therapy) in 2010. Although left ventricular (LV) assist technology to provide mechanical circulatory assistance for the failing heart has existed since 1963, it has only been in the last decade, with the advent of a continuous-flow pump, that these devices have become capable of providing reliable long-term support.^4,5 Based on data from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), the number of LVADs implanted increased nearly sixfold from 276 in 2006 to an estimated 1,600 patients in 2011.⁶ Among the 5,407 patients with LVADs registered in INTERMACS, approximately ¾ had devices placed as a bridge to transplant, and ¼ had them placed as a destination therapy.⁶ As the number of patients with LVADs continues to rise and as their survival improves, the emergency physician will increasingly be tasked with their acute care. This review focuses on a single LVAD system, the HeartMate II (Thoratec, Pleasanton, CA); this is the most commonly-installed assist device worldwide, and knowledge of this system is applicable to the management of other continuous-flow systems. This chapter addresses (1) the evolution of the LVAD, (2) the management of LVAD-associated complications, and (3) the use of radiographic imaging in diagnosing these complications.

EVOLUTION AND GENERAL FUNCTION OF LEFT VENTRICULAR ASSIST DEVICES

The two main groups of LVADs are distinguished by pump type: pulsatile and continuous flow (Fig. 18.1). Pulsatile pumps are analogous to the heart: a pumping chamber, once filled, activates a pusher plate technology.⁷ Newer continuous-flow pumps utilize a valveless system, in which centrifugal or axial pumping propels blood forward (Fig. 18.1B). Compared to the pulsatile system, continuous-flow pumps are smaller, lighter (0.75 vs. 2.6 pounds), and quieter. The Randomized Evaluation of Mechanical Assistance for Congestive Heart Failure (REMATCH) trial demonstrated the pulsatile LVAD HeartMate XVE superior to medical therapy.⁸ Patients with the HeartMate XVE had a 1-year survival rate of 52% and a 2-year survival rate of 23%; patients with medical therapy had a 1-year survival of 25% and a 2-year survival rate of 8%.⁸ A follow-up trial compared the HeartMate XVE to the continuous-flow HeartMate II for use as destination therapy.⁵ Patients with the pulsatile-flow pump had a 1-year survival rate of 55% and a 2-year survival rate of 24%; patients with the continuous-flow pump had a 1-year survival rate of 68% and a 2-year survival rate of 58%. Continuous-flow devices outperformed pulsatile pumps in rates of rehospitalization, pump replacement, and LVAD- and non-LVAD–related infections.⁵ Adverse events associated with continuous-flow devices included hemorrhagic stroke (9%), right heart failure (5%), sepsis (4%), and bleeding (3%); the rate of these complications was, however, not significantly different from that of pulsatile-flow devices.⁵ This trial highlighted the primary advantages of continuous-flow over pulsatile devices, namely, improved reliability and decreased pump wear, a lighter weight and less cumbersome design, and lower infection risk.⁹ Newer second-generation LVADs include the HeartWare system (HeartWare, Framingham, MA, approved for bridge to transplant); this smaller “wearless” device is implantable within the pericardium, suspended by a passive magnet and a hydrodynamic thrust-bearing system.¹⁰

PUMP PARAMETERS

General Considerations

All LVAD flow parameters are set at the time of implantation; for the emergency physician needing to diagnose and manage acute illness and device-related complications in LVAD users, understanding the parameters displayed and their significance is essential. The HeartMate II control monitor displays the following parameters: pump speed (revolutions per minute [RPM]), pump power (watts [W]), flow estimate (liters per minute [LPM]), and pulse index (dimensionless value). Commonly, clinicians inexperienced with LVAD management will make decisions based on single parameters (e.g., decreased flow), failing to understand the significance of this parameter in the context of an acute change in condition. Instead, when troubleshooting a patient with an LVAD, clinicians should gather data from the whole patient, assessing volume status, presence of arrhythmias, mean arterial pressure (MAP), date of LVAD placement, recent echocardiography results, pump parameters, and history of LVAD alarms (e.g., suction events). Deviation from a functional baseline is more significant than the specific value of each parameter. Acquisition of additional hemodynamic data often requires use of echocardiography and pulmonary artery catheters (PACs).

Pump Speed

Pump speed is a fixed value set intraoperatively and often reassessed prior to hospital discharge in a process known as a “ramp study.” This involves empirically adjusting pump speed under echocardiographic guidance to determine the patient’s optimal LV cavity size and output at a given speed. Pump speed governs flow through the device and is a measure of assistance provided to the patient. Only an experienced VAD clinician should adjust pump speed, and always under echocardiographic guidance. Excessive pump speeds may be associated with ventricular arrhythmias.

Pump Power

The HeartMate II controller directly measures the amount of power delivered to maintain pump speed. This parameter is analogous to myocardial workload in normal individuals. An increase in speed, preload, or afterload will increase power consumption. In the absence of these conditions, a gradual increase in power use may indicate the formation of clot on the rotor (see Thrombotic Complications). Conversely, a decrease in afterload, preload, or speed as well as a blockage of inflow or outflow cannula will decrease power consumption. There is no generalizable power level, as it can vary from patient to patient; rather, it is the change (>2 W) from a previous level that may indicate a change in device or patient status.

Flow Estimate

The flow on the HeartMate II is derived from power and speed. Flow is not directly measured but rather is an estimate of the amount of fluid passing through the pump, assuming normal pump function. Using an ultrasonic probe, one study evaluated the differences between the “flow estimate,” as reported on the HeartMate II control monitor, and the “absolute flow” measured by the probe. The study showed that at a flow of 4 to 6 LPM, there was a variable 15% to 20% difference between the estimated and absolute flow values.¹¹ Several factors affect “absolute flow” for continuous pumps; these include preload (LV preload and right ventricular [RV] function), speed, and afterload (the difference between outlet cannula and inlet cannula pressure).⁹ Thus, hypervolemia, increased LV contractility, increased speed, and decreased pressure difference across the pump will increase flow. As mentioned, situations such as a clot on the rotor will cause power to increase, resulting in an erroneously high flow displayed as “+++.” Flows displayed as “+++” or “−−−” (for high and low flows, respectively) are considered outside the range of the expected physiologic limits based on speed.⁹ The HeartMate II low-flow alarm will signal when flow is <2.5 LPM. It is important to recognize that “flow estimate” is not analogous to cardiac output or “absolute flow” through the LVAD and thus should be used as a trended, directional value rather than a diagnostic tool to be used alone and without other patient and LVAD values.¹¹

Pulse Index

Pulse index refers to the amount of flow that passes through the pump during a cardiac cycle as averaged over 15 seconds. It is calculated as [(flow max – flow minimum)/flow average] × 10.⁹ It is a dimensionless value that is derived from the LVAD estimated flow. The degree of LVAD support is the primary variable that correlates with pulse index, and the two are inversely related. During LV systole, the flow through the pump increases due to an increased pressure at the pump inlet approximating the pressure at the outlet cannula (aortic pressure). During cardiac diastole, this inlet pressure drops, while the outlet pressure remains high (increased pressure difference) and, consequently, flow decreases. Therefore, pulse index is directly proportional to LV contractility (increases in which are due to preload, inotropic support, and myocardial recovery) and inversely proportional to the assistance provided by the pump.

ADVERSE EVENTS AND COMPLICATIONS

Common LVAD-related complications include hemorrhage, arrhythmias, infections, hemodynamic instability, and thrombosis (Table 18.1).^5,13 When any of these are encountered in an LVAD-supported patient, a multidisciplinary approach to management is required; the patient’s cardiologist and/or VAD coordinator should be contacted to discuss the plan of care. If hospitalization is indicated, then the patient should be transferred to a VAD center when stable for transport.

Infections

Infections are common in LVAD patients and are a leading cause of hospital readmission and mortality.^5,13–17 Based on an analysis of 2,006 patients registered in the INTERMACS database, nearly 19% of patients will develop a percutaneous site infection within 1 year.¹⁴ The percutaneous lead acts as a portal of entry for pathogens, which can progress to the subcutaneous tunnel, pump pocket, device, heart (i.e., endocarditis), and bloodstream (Figs. 18.2 and 18.3). Recommendations for the evaluation of an LVAD patient with suspected infection are outlined in Table 18.1. Patients with suspected LVAD-related infections should be treated with empiric broad-spectrum antimicrobials to cover nosocomial pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.^16,18 Fungemia has also been reported in LVAD-supported patients.¹⁹ Surgical consultation should be obtained, as incision and drainage, debridement, and/or percutaneous lead revision may be required.¹⁶ The ongoing development of LVADs that do not require a percutaneous lead should reduce the risk of these infections.

Hypotension and Hemodynamic Instability

Continuous-flow pumps unload the LV throughout the cardiac cycle, resulting in a diminished or absent pulse pressure.²⁰ Thus, noninvasive measurement of blood pressure and pulse oximetry are often unreliable.⁹ Blood pressure is best measured as a mean arterial pressure (MAP) obtained by Doppler and sphygmomanometer or, alternatively, by placement of an arterial catheter. Goal MAP in most LVAD patients is 70 to 80 mm Hg. In general, MAP should not exceed 90 mm Hg; LVAD patients are sensitive to increases in afterload, and higher blood pressures increase their risk for adverse neurological events.⁹ For the hypertensive LVAD patient, beta-blockers and angiotensin-converting enzyme inhibitors are generally used for blood pressure control. For the hypotensive patient, the etiology should be identified (hypovolemic, vasodilatory, or cardiogenic shock due to RV or LV failure) and treated accordingly with volume repletion, vasopressor, and/or inotropic medications. Echocardiography and pulmonary artery catheterization may provide valuable data for diagnosis and management. Additionally, problems intrinsic to the device, such as oversuctioning, may contribute to diminished blood flow and should be considered when evaluating the hypotensive LVAD patient.

Right Ventricular Failure

Right ventricular failure (RVF) is one of the more dreaded etiologies of hypotension after LVAD placement. RVF is estimated to occur in up to 20% of LVAD patients²¹ and is associated with a 1-year mortality of 83%.²² While this condition is usually recognized in the immediate perioperative period, the emergency physician may have to contend with the management of LVAD patients with RV dysfunction. Because of the complexity of managing an LVAD patient with RVF, early consultation with a VAD specialist or a cardiologist is recommended, as the patient may require more advanced mechanical circulatory assistance. Causes of RVF specific to LVADs include (1) leftward bowing of the intraventricular septum due to LVAD-related LV emptying, reducing its capacity to participate in RV contractility, and (2) increased venous return from the LVAD, outmatching the capacity of a failing right heart.²³ Table 18.1 details the management strategy for patients with RVF, including transfer to a critical care unit for placement of a pulmonary artery catheter (PAC) and/or transesophageal echocardiography. Among inotropes, milrinone is particularly beneficial because it decreases pulmonary vascular resistance (PVR) and improves RV contractility and matching of RV and LVAD outputs.²⁴ Additional therapies for RVF include pulmonary vasodilators, such as inhaled nitric oxide (iNO) and/or aerosolized prostacyclin, that lower PVR. Avoidance of conditions that aggravate pulmonary vasoconstriction, such as hypercapnia and hypoxemia, is also essential. In a randomized trial of 11 patients with increased PVR after LVAD placement, iNO significantly reduced PVR and increased LVAD flow in patients with pulmonary hypertension.²⁵ Avoidance of excessive preload is also important in the management of patients with RVF; thus, particular caution should be paid to the LVAD patient with a history of RVF who presents to the emergency department with hemorrhagic shock and who may require large-volume blood and factor transfusions. Patients who do not respond to these medical therapies for RVF (e.g., iNO, inotropes) may require more advanced mechanical circulatory support including the placement of a right ventricular assist device (RVAD). Risk factors that predict the need for an RVAD placement include female gender, low right ventricular stroke work index, history of pulmonary hypertension, and intraoperative high central venous pressure.^21,22,26,27

Suction Events

A suction event occurs when there is excessive LV unloading due to a pump speed that is too high relative to LV volume. Suction events may manifest as a decrease in pump flow, arrhythmias, or transient and intermittent decreases in the pump speed to the low-speed limit (a result of LVAD auto-correction). During a suction event, echocardiography will demonstrate a leftward shift of the intraventricular septum with an underfilled LV. Other potential causes of poor LV filling include hypovolemia, RVF, pulmonary hypertension, and malposition of the inflow cannula toward the intraventricular septum or the lateral wall (Fig. 18.4). Suction events can be alleviated by volume repletion or by decreasing the pump speed, tasks best performed by an LVAD specialist using echocardiographic guidance.

Related posts:

Extracorporeal Membrane Oxygenation Sickle Cell Disease Transfusion Therapy The Central Venous and Pulmonary Artery Catheter Pancreatitis Subarachnoid and Intracerebral Hemorrhage